Does the target dose of neurohormonal blockade matter for outcome in Systolic heart failure in octogenarians?

A tool for assessment of heart failure prescribing quality: A systematic review and meta‐analysis

“…The increasing proportion of high GAI rates reported from 2005 to 2016 supports this. However, there is still room for optimising target dose prescribing as the combined levels of target dose achievement in this review were lower than those reported recently by Barywani et al…”

“…It has been shown that underprescribing of evidence‐based therapies is associated with worsening HF and higher rates of HF hospital admissions and mortality . Furthermore, where these disease‐modifying agents are prescribed but at lower than target dose, patients may not obtain the full beneficial effect of the agent . Thus, HF care could be vastly improved with optimal use of guideline‐directed therapy …”

“…Furthermore, where these disease‐modifying agents are prescribed but at lower than target dose, patients may not obtain the full beneficial effect of the agent . Thus, HF care could be vastly improved with optimal use of guideline‐directed therapy …”

“…patients may not obtain the full beneficial effect of the agent. 5,10 Thus, HF care could be vastly improved with optimal use of guideline-directed therapy. 10,11 Guideline adherence refers to the adoption of clinical guidelines by clinicians, rather than to the patient's own adherence.…”

“…5,10 Thus, HF care could be vastly improved with optimal use of guideline-directed therapy. 10,11 Guideline adherence refers to the adoption of clinical guidelines by clinicians, rather than to the patient's own adherence. There remains a wide variation in HF prescribing patterns and quality internationally, 5,12,13 and several barriers to guideline adherence have been described.…”